What type of study is this?

September 18, 2025BMJ OpenOpen Access

Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol

View Full Paper

Ask AI

Bookmark

Tirzepatide use in type 1 diabetes may improve body weight outcomes by targeting insulin resistance and glycaemic control.
The trial seeks a significant reduction in body weight, measuring compliance and adverse events among 60 participants aged 18–70.
Conducted as a double-blind, placebo-controlled randomised trial, data will be analysed using independent samples t-tests and significance thresholds set at p<0.05.
The research highlights a potential new avenue for treatment in individuals struggling with weight management amid type 1 diabetes.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This randomised controlled trial assesses tirzepatide's impact on glycaemic control and weight loss in adults with type 1 diabetes and obesity, suggesting a novel therapeutic approach.

Cite This Study

Purcell et al. (2025) studied this question.

synapsesocial.com/papers/68d462d231b076d99fa626e2 https://doi.org/10.1136/bmjopen-2024-093775

View Full Paper

Ask AI

Bookmark

Implication

This randomised controlled trial assesses tirzepatide's impact on glycaemic control and weight loss in adults with type 1 diabetes and obesity, suggesting a novel therapeutic approach.

Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol

Key Points

Discussion

Implication

Cite This Study

Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider